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Relation between renal calcium content and renal impairment in 246
human renal biopsies. Tissue calcium content from 246 diagnostic
human renal biopsies was measured to assess whether elevated tissue
calcium concentration could be demonstrated to exist early during the
course of human renal disease or was only a manifestation of advanced
renal impairment. Renal calcium content correlated significantly with
serum creatinine (r = +0.23, P < 0.001, N = 246); serum phosphate (r
= +0.27, P < 0.001, N = 169) but not with serum calcium (r = —0.10,
P> 0.1, N = 193). Fivefold greater calcium content was measured in
biopsied patients with normal renal function than in normal postmortem
renal tissue (35.7 5.2 vs. 7.6 0.7 mgCa/100 g wet renal tissue, P <
0.001). Those biopsied patients with significant functional impairment
(SCr > 1.5 mg/dl) had a higher mean level of serum phosphorus and
serum [Ca] x [P1 product than patients with normal renal function (5.19
0.22 vs. 3.92 0.11 mg P/dI and 44.8 1.8 vs. 35.7 1.2 mg2/d12,
respectively), and slightly higher renal calcium content (85.3 32.2 vs.
35.7 5.2 CaJlOO g wet renal tissue, P = 0.06), which correlated with
histologic calcium deposition (r = +0.52, P < 0.02, N = 20). These
findings are consistent with the hypothesis that renal calcium deposition
begins early in the course of a variety of renal diseases and hence may
play a secondary pathogenetic role that accelerates progression to
chronic renal failure. Severity of renal calcium deposition is equally
closely related to hyperphosphatemia and to the level of renal impair-
ment.
Nephrocalcinosis with ensuing chronic interstitial inflamma-
tion may accelerate deterioration in renal function and progres-
sion of renal disease in humans [1—3]. Calcium deposits have
been well documented in kidneys and other tissues of uremic
patients [4, 5], particularly in conditions such as hyperpara-
thyroidism [6, 7], vitamin D intoxication [8] and milk alkali
syndrome [9]. In experimental uremia progressive functional
renal impairment can be easily induced by increased dietary
phosphate [10], administration of PTH [11, 12] or vitamin D
[12], parenteral loading of phosphate [13] or calcium [14], and
reduction in the amount of functional renal mass [15]. The
common histopathologic feature in these experiments is the
development of nephrocalcinosis with chronic interstitial in-
flammation and scarring. There is resulting functional impair-
ment and ultimately, death of the animal follows. This pattern
of events and morphologic alterations was first demonstrated in
phosphate induced nephrotoxicity by MacKay and Oliver [16].
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Data relating to calcium deposition have been unavailable in
humans early in the course of renal failure when serum creati-
nine is still within normal range. In animals with nephrocalci-
nosis produced by the infusion of phosphate [13], calcium or
PTH [17], however, this deposition has been found to be an
early event which not only worsens as renal impairment
progresses but correlates with the degree of functional renal
deterioration.
Ibels et al [18] recently reported that the calcium content of
kidneys from patients with ESRD is eightfold greater than that
found in normal kidneys, a finding consistent with a pathogenic
role for nephrocalcinosis as a contributor to the progression of
renal failure. It is still not known whether abnormal calcium
deposition occurs early in human renal disease, and if so,
whether it is possible to prevent or reduce such early deposi-
tion. We have addressed the first of these issues by examining
the calcium content of renal tissue obtained at diagnostic biopsy
from patients with a wide range of severity of renal impairment.
The present study is focused particularly upon three questions.
1.) Can a correlation be demonstrated between renal calcium
content and the degree of functional impairment? 2.) Is the
process of calcium deposition an early or late event in the
natural history of progressive renal disease? 3.) Can hyperphos-
phatemia be related to increased deposition of calcium and thus
possibly incriminated as a determinant of renal calcification in
human renal disease?
Methods
Kidney tissue was obtained from 246 patients who underwent
either diagnostic renal biopsy for a variety of renal diseases or
nephrectomy at the Johns Hopkins Hospital between 1976 and
1980. The specimens were quickly frozen in liquid nitrogen and
kept at —70°C after first being embedded in O.C.T., a commer-
cial mixture prepared by Miles Laboratories (Elkhart, Indiana,
USA) which contains distilled water, carbowax, and dimethyl-
benzoyl—ammonium chloride which prevented dehydration.
Further analysis by atomic absorption spectrophotometry of
this fixative in our laboratory did not show evidence of calcium
within its components. Tissues for controls were obtained from
autopsied patients who died from unrelated causes, had no
history of renal disease, hypertension or urinary abnormalities
during life. These patients exhibited no clinical or microscopic
evidence of diseased kidneys and at time of autopsy their
kidneys had a normal appearance; they resembled the biopsied
patients otherwise (Table 1).
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Table 1. Demographic data for patients grouped by serum creatinine levels
N Age yrs Body wt kg Sex M/F Race BIW SCr mg/dl
Patients
SCr <
Patients
SCr>
Controls
1.5
1.5
122
124
19
35.3 + 19.5
40.5 + 19.2
34.5 + 21.8
61.6 + 26.7
61.0 + 19.3
65.2 + 18.9
49/73
75/48
14/5
35/68
21/76a
6/13
0.99 + 0.28
7.66 + 6.06
1.03 + 0.28
All values are mean + SD.
a There were two orientals in each group.
gCa/mg tissue DNA
Fig. 1. Correlation between two methods of expressing renal Ca con-
tent. The scales of both axes in this graph are logarithmic. A spuriously
high weight caused by contamination with the preservation media used
for freezing should have yielded a negative intercept for the linear
regression equation relating the two methods of expressing the tissue
calcium content. In fact, the intercept as shown in the equation is +0.36
(±0.185); thus measurement of calcium in frozen needle biopsy speci-
mens and expression/unit wet weight of tissue provides a satisfactory
estimate of calcium content.
Histological diagnosis N
Glomerular diseases 133
Interstitial diseases 31
Vascular diseases 16
End—stage kidneys 27
Miscellaneous 39
Norma1sa 19
a
Each sample was thawed immediately before assay and
weighed individually on a model B5 Mettler high precision
analytic balance, (Mettler Instrument Corporation, Highstown,
New Jersey, USA) and subsequently placed into a small pyrex
assay tube (which had been previously rinsed with diluted HC1)
and digested with 0.1 cc of a 12 N solution of HC1 under heat to
total dissolution. Calcium determinations were made on the
acid digests [19], using a model 251 atomic absorption spectro-
photometer from Instrumentation Laboratories (Lexington,
Massachusetts, USA). Values were expressed as mg cal-
ciumll0O g of wet kidney tissue. To check for accuracy and
screen for a potential source of variability (particularly for
falsely high weight contributed by the O.C.T. fluid), 57 of these
samples were also simultaneously assayed for tissue DNA
content [201. Tissue calcium content was then re-expressed as
g calcium/mg DNA and the results of the two methods
compared,(r = +0.91,P < .001, jxgCalmg tissue =0.36 + 0.004
x p.gCa/mg DNA). Thus the content of O.C.T. in the samples
had a negligible influence upon the determination of tissue
calcium content expressed on the basis of wet tissue weight
(Fig. 1).
Serum creatinine determinations which provided an index of
renal function were performed following the method of Jaffe
[21]; serum calcium levels were measured following a method
described elsewhere [19] as were serum phosphate levels [22].
Statistical analyses included Wilcoxon's two group rank sum
test, Pearson's product moment correlation coefficient and
Spearman's rank correlation coefficient where appropriate.
Results
The renal biopsies subjected to this analysis represented a
variety of different disease categories (see Table 2). The mis-
cellaneous category includes five with essential hematuria, five
with tumors elsewhere in the kidney, eight with polycystic
kidney disease, two with cortical necrosis, four with hereditary
nephritis, four with hydronephrotic kidneys, six transplant
biopsies, one from a patient with sickle cell anemia, one from a
patient with a renal stone and three samples which had medul-
lary tissue only.
The complete data set was examined for correlations between
renal tissue calcium, serum creatinine, serum calcium, serum
phosphate and serum [Ca] x [P1 product. Age as a possible
confounding variable was evaluated since renal function is
known to decline with age [23]. Kidney calcium content corre-
lated with serum creatinine (r = +0.23, P < .001, N = 246, Fig.
2), with the level of serum phosphate (r = +0.27, P < 0.001, N
= 169) and with serum [Ca] x [P1 product (r = +0.22, P =
0.005; N = 165), but not with serum calcium levels (r = —0.10,
P > 0.1, N 193, Table 3). Moreover, mean serum levels of
phosphate were significantly elevated among those patients
who had a serum creatinine of >1.5 mg/dl when compared with
a normal (<1.5 mg/dl) serum creatinine, (phosphate levels were
5.2 mg/dl and 3.9 mg/dl, respectively, P <0.001). On the other
hand, mean serum calcium levels did not differ between these
two groups, (P = 0.07, Table 4). Elevation of serum [Ca] x [P1
product, found also to be significantly different for these two
groups, (P < 0.001, Table 4), was due to an elevation in the
serum phosphate levels. Furthermore, serum phosphate was
strongly correlated with serum creatinine (r = +0.48, P <
0.001, N = 246) (Table 3) indicating that as renal function
deteriorates there is a progressive impairment in phosphate
148.5
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Table 2. Disease categories for the study group
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Table 3. Bivariate correlation coefficients between selected
parameters from 246 patients with renal disease
TCa SCa SPO4 Age
SCr +0.23a —0.09 +0.48a +0.11
TCa —0.10 ÷0.27a +0.01
SCa —0.09 —0.18
SP04 —0.13
r values are Pearson's correlation coefficient
a P < 0.001
2.7 7.4 20.0 56.0 148.4 403.4 1,096.6 2,981.0
Renal Ca content mg Ca/bOg wet tissue
Fig. 2. Linear regression analysis between renal calcium content and
serum creatinine for all tissues analyzed. Patients are depicted by (•)
and controls by (x). The correlation coefficient is +0.27 (P < 0.001; N
= 265). The linear equation is SCr = 1.029 + 1.288 X tissue calcium.
excretion with secondary elevation of the serum [Ca] x [P1
product.
When multiple linear regression analysis (mult r), with renal
tissue calcium as the dependent variable, was calculated for
serum creatinine, serum phosphate and serum [Ca] x [P1
product as independent variables, the relationship remained a
significant one, (mult r = 0.34, P < 0.001). Partial correlation
coefficients were significant for serum creatinine, (r = + 0.25, P
= 0.001) and serum [Ca] x [P1 product (r = +0.22, P = 0.005)
but not for serum calcium (r = —0.06, P = 0.5). The highly
significant bivariate correlation between serum P04 and tissue
Ca (r = +0.3, P < 0.001), is reduced to marginal significance as
a partial correlation when creatinine is controlled (r = +0.15, P
= 0.05), a reflection of the fact that the elevation in serum
phosphate is in itself highly dependent on the level of renal
function (r = +0.48, P < 0.001, Table 3).
Further testing was done by comparing data from patients
whose serum creatinine levels were <1.5 mg/dl at time of
biopsy, (that is, patients with histologic evidence of renal
disease but presumably preserved renal function), and those
with serum creatinine levels of >1.5 mg/dl, (patients with
functionally as well as anatomically impaired kidneys). Signif-
icant differences were demonstrated in serum phosphate (P <
0.001) and serum [Ca] x [P1 product (P < 0.001); tissue calcium
content was higher in the group with renal impairment but not
significantly so. Both groups, however, did have significantly
higher amounts of tissue calcium than did the normals (P <
0.001 for both groups, Fig. 3). This observation indicates that
the calcium content increases in histologically diseased kidneys
even before significant deterioration in renal function occurs.
Neither serum phosphate, tissue calcium, serum calcium or
serum [Ca] x [P1 product correlated with age, thereby exclud-
ing a potentially confounding influence. Moreover, we were
unable to show in the population at study a relationship
between serum creatinine and age (Table 3) in the biopsy group.
Histologic findings
Histologic sections stained with von Kossa stain for phos-
phate were examined in 42 randomly selected cases who had a
tissue calcium of 30 mg/lOO g tissue or higher. These were
examined under polarized light (to detect oxalate) and graded 0
to 3+ for calcium phosphate or calcium oxalate deposition by
one of us (K.S.). Twenty of the 42 cases had calcium deposits
detected histologically. In these 20 cases, there was a significant
correlation by the Spearman rank test between histologic grade
and tissue calcium content (r = 0.52, P < 0.02; Fig. 4). Cases
with predominantly calcium oxalate deposition tended to have a
lower level of tissue calcium (93 31 mg/lOO g, range 35 to 225)
compared with cases with predominantly calcium phosphate
deposition (471 268 mg/l00 g, range 30 to 3721). The
calcification observed histologically was not simply a dystro-
phic phenomenon in heavily scarred tissue but frequently
occurred in areas of relatively intact renal parenchyma. Large
crystals were seen in tubular lumina and occasional capillaries,
as well as free in the interstitium. Finely—granular von Kos-
sa—positive material was also seen in the interstitium in occa-
sional cases with high tissue calcium content (Fig. 5). The mean
tissue calcium content tended to be lower in cases with pre-
dominantly intratubular calcium deposition (128 46 mg/lOO g,
range 33 to 542) as opposed to those cases with predomi-
nantly—interstitial calcium deposits (254 162 mg/l00 g, range
38 to 3721; all values: mean SEM). Because of the large
scatter, this difference was not statistically significant.
Discussion
These data indicate that at least two conditions are associated
with increased calcium deposition in diseased renal tissue in
humans: hyperphosphatemia and an elevated serum [Cal x [P1
product. The hyperphosphatemia results from failure in the
excretion of the dietary phosphate load by the diseased kidney
[24, 25] and almost certainly leads to persistent hyperpara-
thyroidism by decreasing serum ionized calcium [26], resulting
in mobilization of calcium from bone. The elevated serum [Ca]
x [P] product, which is characteristic of the uremic state,
exceeds the solubility product of this ion pair, favoring meta-
static calcification [27, 28]. Excess PTH, almost universally
present in chronic renal failure [29, 30], seems necessary for the
development of nephrocalcinosis. PTH levels were not mea-
sured in the present study, but the observation of abnormally
low serum calcium (Group I: 8.98 0.90; Group II: 8.76 0.97
mg/dl; both values mean SD) and elevated serum phosphate
levels in those patients with and without renal functional
impairment in the present study, represent findings consistent
with elevated serum PTH [30], as well as impaired vitamin D
metabolism [31]. This relationship between the serum levels of
phosphate and serum levels of PTH has been well—documented
in chronic renal failure [30], and the present findings suggest
that this probably occurs quite early during the course of
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Table 4. Comparison of data from biopsy material in patients with normal and impaired renal function
Group I Group II
Variable Controls P values SCr < 1.5 mgldl P valuea SCr> 1.5 mgldl
Serum Cr. mgldl 1.03 0.07 N = 19 NS 0.99 0.02 N = 122 < 0.001 7.66 0.54 N = 124
Tiss. Ca mg/100 g tiss 7.6 0.66 N = l9 < 0.001 35.7 5.2 N = 122 0.06 85.3 32.3 N = 124
Serum Ca tng/dl 9.02 0.33 N = 13 NS 8.98 0.09 N 95 0.07 8.76 0.10 N = 98
Serum P04 mg/dl
Serum CaxP mg2/d12
3.44 0.29 N =
30.3 2.5 N =
12
12
NS
NS
3.92 0.11 N 81
35.7 1.2 N = 80
<0.001
<0.001
5.19 0.22 N = 88
44.8 1.8 N = 85
All values are mean SEM
Wilcoxon's non-parametric rank sum test for unpaired data
P<o.ooi ()
150
P<0.03 ()
(46)
(*)
1
(16)
100
I
50
0 Normals 0—2.9 3—5.9 6—8.9 >9.0
Patients grouped by serum Cr, mg/dI
Fig. 3. Comparison of calcium content measured in biopsy specimens
from patients with renal impairment of increasing severity and post-
mortem renal tissue obtained by needle biopsy from subjects who had
no clinical or laboratory evidence of renal disease and had normal
urinalyses. Wilcoxon's non-parametric rank sum test (*) was used for
statistical evaluation of the data because calcium values in the diseased
kidneys were not normally distributed. The numbers in parenthesis at
the top of each bar represent sample size for each group.
0
2,981.0
V
0
. 1,096.6
0 Fig. 5. Von Kossa stain for calcium phosphate showing spherical
403.4 crystals (right lower arrow) and small punct ate calcific deposits (top left
o arrows), in a nephreciomy specimen from a patient who had end—stage
142.4
diabetic glomerulosclerosis with a calcium content of 1,377 mg/100 g
wet tissue calcium content (X400).
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o evident upon examination of the kidney calcium content from
patients with histologically impaired kidneys but serum creat-
mines within the normal range (Group I), and patients with both
0 0.5 1.0 1.5 2.0 2.5 3.0 functional and histopathologically impaired kidneys (Group II
Histologic rank Fig. 2). The significant positive correlation for tissue calcium
Fig. 4. The linear regression between histologic rank and quantified content and serum creatinine for all patients studied represents
tissue calcium for a group of 20 biopsies. Spearman rank correlation of further evidence that these two variables may be causally
the same data was also significant (r = +0.52; P < 0.02). related.
This progressive accumulation of calcium in kidneys whose
disease, before serum creatinine measurements provide a reli- function declines with time is most closely related to and is
able estimate of impairment of glomerular filtration rate. probably determined by the increased concentration of serum
This relation between tissue calcium and renal function is inorganic phosphate which results from progressive decrease in
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renal function [321. The associated increase in serum [Ca] x [P1
product may well be the proximate cause of this increased
calcium deposition, but the elevated serum phosphate seems to
be the most important factor in initiating the sequence neces-
sary for the development of nephrocalcinosis. Serum calcium
levels did not differ between patients with and without impaired
renal function.
Acute or rapidly developing hyperphosphatemia and the
development of severe renal functional impairment in isolated
cases has been reported with [33, 34], and without [351 simul-
taneous development of soft tissue calcification. In two reports
[341 the temporal relationship between development of hyper-
phosphatemia and rise in serum creatinine have been clearly
documented; furthermore, in one of the cases [36] when hyper-
phosphatemia was corrected, renal function improved substan-
tially, although its failure to return to normal indicates that
some of the changes produced by severe hyperphosphatemia
may indeed be irreversible.
Increased calcium deposition and the accompanying intersti-
tial inflammation accelerate the loss of renal function in animal
models of uremia [10], and rigid restriction of dietary phosphate
preserves renal function with increased survival [15, 37]. Sim-
ilarly, our previous studies [38] and others [39] have shown that
agents which prevent nephrocalcinosis are also effective in
preserving renal function despite increased dietary phosphate
intake.
This nephrocalcinosis and associated renal damage may also
be reversible in patients with end—stage renal disease as noted
by Walser, Mitch and Collier [2, 3].
The alternate hypothesis, that calcium deposition may occur
as a secondary event in previously scarred tissue and, there-
fore, not be a direct contributor to further functional deteriora-
tion can be excluded by what we have observed in the histologic
examination of renal tissue of these patients. Calcium deposits
were frequently found in areas of relatively—intact renal paren-
chyma, in the form of discrete intratubular or interstitial calci-
fication.
Maschio and colleagues [40] reported recently that by re-
stricting dietary phosphorus by 28% of average normal dietary
intake and limiting protein intake, in a group of patients with
mild renal failure (mean serum creatinine of 2.2 mgldl), the
average rate of decline in renal function was substantially
reduced. This reduction was associated with lower levels of
serum phosphate.
Our findings extend the initial report of Ibels and colleagues
[18], and demonstrate that the calcium content from kidneys
with different types of renal disease is significantly higher than
that seen in normal kidneys. The findings here indicate that
increased calcium deposition begins early in the course of renal
disease and can be demonstrated in patients with serum creat-
mine of <1.5 mgldl, who have histologic evidence of renal
disease. Values for tissue calcium in such patients exceeded
that for normal kidneys by more than fourfold. Furthermore,
this process seems to be quite dependent on the level of serum
phosphate. We interpret these findings to indicate that hyper-
phosphatemia occurs quite early in renal impairment before
significant decline in GFR can be documented by monitoring
serum creatinine. It seems most likely that the hyperphospha-
temia is transient and recurrent and may occur only after meals,
since fasting phosphates are usually normal in patients with
serum creatinines less than 1.5 mg/dl.
Barsotti et al [41] provided evidence that at least part of the
benefit of protein restriction could be attributed to reduction in
phosphate intake. Although the decrement in nitrogenous di-
etary intake exerted a beneficial effect, this effect was signifi-
cantly increased when the dietary phosphorus was also simul-
taneously restricted by 50%. Our results support their finding of
a significant correlation between the level of renal function and
serum phosphate concentrations, and we have demonstrated
that this also correlated with tissue calcium deposition. Further
corroboration of the relation between phosphate intake and
renal damage comes from studies in animals with 5/6 reduction
of renal mass fed a diet with normal phosphate content [42].
Within 48 to 72 hours of phosphate loading or PTH infusion in
rats [17], there are ultrastructural cellular changes in proximal
tubular mitochondria, not visible by light microscopy, that
appear consistent with apatite deposition, resulting in extensive
disruption of normal mitochrondrial structure. These ultrastruc-
tural changes, demonstrable within two days after phosphate
loading, were still almost undetectable by light microscopy after
ten days despite a renal calcium content six times higher than
controls [13]. Experimental models of acute renal failure in-
duced by gentamicin, HgC12 and ischemia [43, 44], have exhib-
ited an early significant increase in the amount of intramito-
chondrial calcium accumulation. This process correlates with
the degree of functional renal impairment [43], suggesting a
possible role of calcium in renal cell death. It is known that
intramitochondrial calcium accumulation interferes with oxida-
tive phosphorylation [45] and early mitochondrial calcium ac-
cumulation has been demonstrated in several experimental
models of renal damage.
In clinical renal disease, phosphate may have an etiological
role per se in the intracellular accumulation of calcium with
calcium phosphate deposition in a sequence analogous to that
demonstrated in cultured kidney cells, where phosphate pro-
duces an increase in the intracellular calcium pool, probably
mostly in the mitochondria [46]. The present study documents
an association between progressively—impaired renal function,
renal calcium content and serum phosphate in biopsy material
from a wide variety of renal diseases. It seems likely that these
findings are linked to the early alterations in intracellular
calcium and mitochondrial damage described above. This sug-
gests that calcium deposition may be an extremely—important
secondary factor in determining the rate of damage seen in
many renal diseases. The relation of this progressive increase in
abnormal calcium deposition within the kidney to the recently—
demonstrated adverse effects of hyperperfusion of the glomeruli
in progressive renal impairment [47—49] remains to be deter-
mined.
The strong association between this increased tissue calcium
and serum phosphate that can be demonstrated quite early in
the course of renal disease strongly incriminates dietary phos-
phate as an important factor in determining rate of renal
function decline, and forces attention upon dietary phosphate
restriction as an early therapeutic intervention that may be of
considerable benefit [50]. At the least, the hypothesis should be
examined critically.
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